Grandeur Peak Global Advisors LLC Has $251,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Grandeur Peak Global Advisors LLC lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 13.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,591 shares of the company’s stock after selling 250 shares during the period. Grandeur Peak Global Advisors LLC’s holdings in Zoetis were worth $251,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of ZTS. Norges Bank acquired a new position in Zoetis in the fourth quarter worth about $763,474,000. Alliancebernstein L.P. raised its position in Zoetis by 7.1% in the first quarter. Alliancebernstein L.P. now owns 17,823,733 shares of the company’s stock worth $2,806,882,000 after purchasing an additional 1,178,470 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Zoetis by 503.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,161,345 shares of the company’s stock worth $182,889,000 after buying an additional 968,926 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Zoetis by 10.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,062,310 shares of the company’s stock worth $1,584,612,000 after buying an additional 912,551 shares in the last quarter. Finally, Toronto Dominion Bank increased its holdings in shares of Zoetis by 196.9% during the first quarter. Toronto Dominion Bank now owns 880,942 shares of the company’s stock worth $138,729,000 after buying an additional 584,203 shares in the last quarter. 90.03% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently weighed in on the stock. Citigroup raised their price objective on shares of Zoetis from $175.00 to $184.00 in a report on Wednesday, May 12th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price objective for the company in a report on Tuesday, June 1st. Barclays raised their price objective on shares of Zoetis from $200.00 to $208.00 and gave the stock an “overweight” rating in a report on Friday, May 7th. Cantor Fitzgerald raised their price objective on shares of Zoetis from $210.00 to $238.00 and gave the stock an “overweight” rating in a report on Tuesday, July 13th. Finally, increased their price target on shares of Zoetis from $175.00 to $184.00 and gave the company a “neutral” rating in a research note on Wednesday, May 12th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Zoetis currently has an average rating of “Buy” and a consensus price target of $188.21.

In other news, EVP Roxanne Lagano sold 6,000 shares of Zoetis stock in a transaction on Wednesday, May 19th. The shares were sold at an average price of $169.05, for a total transaction of $1,014,300.00. Following the transaction, the executive vice president now directly owns 53,642 shares of the company’s stock, valued at $9,068,180.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.17% of the company’s stock.

ZTS stock traded up $1.14 during midday trading on Thursday, reaching $199.18. The company’s stock had a trading volume of 2,479 shares, compared to its average volume of 1,766,974. Zoetis Inc. has a 52 week low of $141.41 and a 52 week high of $202.04. The stock has a market capitalization of $94.56 billion, a PE ratio of 48.10, a PEG ratio of 3.46 and a beta of 0.65. The company has a debt-to-equity ratio of 1.61, a quick ratio of 2.47 and a current ratio of 3.29. The stock’s 50-day moving average price is $184.54.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.22. Zoetis had a net margin of 25.30% and a return on equity of 55.11%. The firm had revenue of $1.87 billion for the quarter, compared to analysts’ expectations of $1.73 billion. During the same period last year, the firm earned $0.95 earnings per share. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. Analysts predict that Zoetis Inc. will post 4.5 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 1st. Stockholders of record on Wednesday, July 21st will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Tuesday, July 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.50%. Zoetis’s dividend payout ratio is 25.97%.

About Zoetis

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Featured Story: Diluted Earnings Per Share

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.